PRPS2

Across TCGA pan-cancer cohorts, PRPS2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRPS2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PRPS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.328	0.889	.014	20	view →
LUAD	DFS	Median	All	0.944	0.683	.017	2	view →
CCRCC	DFS	Median	III,IV	0.960	0.766	.013	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRPS2–HNSC (DFS)

Open the HNSC breakdown →